FDA End-of-Year Release of Warning Letters Impresses (or Depresses)
FDA Law Blog
JANUARY 1, 2024
Perhaps FDA wanted us to remember 2023 as the year FDA succeeded in uncovering critical defects in drug and device manufacturing, and in critical trials. If FDA wanted to create that impression, it likely succeeded. FDA stated that the firm received 96 U.S. Dextrum Laboratories Inc. Terragene S.A.,
59 
Let's personalize your content